Specific cDNA probes can detect dystrophin gene deletions in a significant proportion of DMD and BMD patients, with higher deletion frequencies observed in sporadic cases, which may inform genetic counseling.
May support probe-based deletion screening in DMD/BMD genetic testing; leaves open whether sporadic cases warrant prioritized counseling pending validation.
We have analysed 38 DMD patients from 34 families and 30 BMD patients from 12 families using the cDNA probes Cf23a and Cf56a, which map near the centre of the dystrophin gene, and Cf115, which is close to the 3' end of this gene. Together, probes Cf23a and Cf56a detected deletions in 50% of the DMD families and 33% of the BMD families. Probe Cf115 detected a deletion in only one DMD patient, which has not been reported before in severe X linked myopathy. Most of the DMD deletions could be detected with Cf56a while all four BMD deletions were detected with Cf23a. The pattern of deletions could not be used to predict the precise clinical course of the disease and no correlation was found between the severity of the disease and the extent of the gene deletion. A higher frequency of deletions was observed in sporadic (73%) compared with familial DMD (28%) and BMD cases (33%). This result, if confirmed in a larger sample, would have important implications for genetic counselling.
No takes yet. Share an insight, caveat, or question.
Passos‐Bueno et al. (1990) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: